Travere Therapeutics, Inc. (TVTX): Capital Expenditures

Annual figures by period end, from SEC filings.

Older than the company's other figures. The latest Capital Expenditures is for the year ended 2023-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report this line under the concept TickerFacts maps.

$668.0K
Year ended 2023-12-31
-53.8%
3-year compound annual growth
-1.7%
5-year compound annual growth
+19.0%
10-year compound annual growth
$6.77M2012-12-31: $24.8K2013-12-31: $117.0K2014-12-31: $663.0K2015-12-31: $22.0K2016-12-31: $1.43M2017-12-31: $887.0K2018-12-31: $727.0K2019-12-31: $195.0K2020-12-31: $6.77M2021-12-31: $5.10M2022-12-31: $191.0K2023-12-31: $668.0K$668.0K
2012-12-31 Capital Expenditures (USD) 2023-12-31
Period endedCapital ExpendituresChange YoYSource filing
2023-12-31$668.0K+249.7%2024-02-20, From 2023-01-01
2022-12-31$191.0K-96.3%2024-02-20, From 2022-01-01
2021-12-31$5.10M-24.6%2024-02-20, From 2021-01-01
2020-12-31$6.77Mn/m2023-02-23, From 2020-01-01
2019-12-31$195.0K-73.2%2022-02-24, From 2019-01-01
2018-12-31$727.0K-18.0%2021-03-01, From 2018-01-01
2017-12-31$887.0K-37.9%2020-02-24, From 2017-01-01
2016-12-31$1.43Mn/m2019-02-26, From 2016-01-01
2015-12-31$22.0K-96.7%2018-07-06, From 2015-01-01
2014-12-31$663.0K+466.7%2017-03-01, From 2014-01-01
2013-12-31$117.0K+372.3%2016-02-26, From 2013-01-01
2012-12-31$24.8Kn/a2015-07-09, From 2012-01-01